![Karim Dabbagh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Karim Dabbagh
Vorsitzender bei
MAAT PHARMA
Vermögen: 851 362 $ am 31.07.2026
Profil
Karim Dabbagh was the founder of Modus Biomedicine, Inc., founded in 2009, and served as Chief Executive Officer from 2009 to 2010.
Current jobs include Chief Executive Officer at Dualitas Therapeutics, Inc. starting in 2026, and Independent Chairman at Maat Pharma SA starting in 2023.
Former job includes President, Chief Executive Officer & Director at Second Genome, Inc. from 2018 to 2023.
Education includes undergraduate studies at Imperial College London and a doctorate from University College London.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MAAT PHARMA 1.41% | 31.03.2025 | 266’173 ( 1.41% ) | 851 362 $ | 31.07.2026 |
Aktive Positionen von Karim Dabbagh
| Unternehmen | Position | Beginn |
|---|---|---|
| MAAT PHARMA | Vorsitzender | 21.06.2023 |
Ehemalige bekannte Positionen von Karim Dabbagh
| Unternehmen | Position | Ende |
|---|---|---|
Second Genome, Inc.
 Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Vorstandsvorsitzender | 01.09.2023 |
Modus Biomedicine, Inc. | Vorstandsvorsitzender | 01.12.2010 |
Ausbildung von Karim Dabbagh
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
33
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Second Genome, Inc.
Second Genome, Inc. BiotechnologyHealth Technology Develops microbiome-based therapeutic products | Health Technology |
Maat Pharma SA
 Maat Pharma SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage company which develops and commercializes patient-microbiome symbiosis to improve survival outcomes in oncology | Health Technology |
Modus Biomedicine, Inc. |
